Abstract
We examined the therapeutic effects of dietary exposure to 5-campestenone (24-methylcholest-5-en-3-one),
an enone derivative of campesterol, in Zucker diabetic fatty (ZDF) rats, an animal
model of type 2 diabetes mellitus. Dietary 0.6 % exposure to 5-campestenone caused
marked reduction in hemoglobin A1c (HbA1c), plasma total cholesterol, triglycerides
and non esterified fatty acid (NEFA). In particular, plasma triglyceride levels were
reduced in the 0.6 % 5-campestenone-fed group to about 25 % of that in the control
group. In the oral glucose tolerance test (OGTT) at three and seven weeks after the
beginning of treatment, 5-campestenone limited the rise of blood glucose levels by
oral administration of glucose dose-dependently. Amounts of adipose tissue in the
retroperitoneum and periepididymal area as well as abdominal subcutaneous fat were
significantly decreased in animals fed 0.6 % 5-campestenone. The blood leptin concentration
on the final day of feeding was significantly in animals administered 5-campestenone.
No obvious anomaly due to consumption of 5-campestenone was detected in necropsy or
clinical observations.
Key words
5-campestenone · Zucker diabetic fatty rat · Body fat (adipose tissue) · Plasma non-esterified
fatty acid · Plasma triglyceride
References
- 1
Lee Y, Hirose H, Ohneda M, Johnson J H, MacGarry J D.
Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus
of obese rats: Impairment in adipocyte-beta-cell-relationships.
Proc Natl Acad Sci USA.
1994;
91
10 878-10 882
- 2
Randle P J, Arland P B, Hales C N, Newsholme E A.
The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances
of diabetes mellitus.
Lancet.
1963;
1
785-789
- 3
Boden G.
Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.
Diabetes.
1997;
46
3-10
- 4
Suzuki K.
Anti-obesity effect of cholest-4-en-3-one, an intestinal catabolite of cholesterol,
on mice.
J Nutr Sci Vitaminol.
1993;
39
537-543
- 5
Suzuki K, Shimizu T, Nakata T.
The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body
weight gain, body fat accumulation and serum lipid concentration in mice.
Bioorg Med Chem Lett.
1998;
8
2133-2138
- 6
Suzuki K, Tanaka M, Konno R, Kaneko Y.
Effect of 5-Campestenone (24-Methylcholest-5-en-3-one) on the Type 2 Diabetes Mellitus
Model Animal C57BL/Ksj-db/db Mice.
Horm Metab Res.
2002;
34
121-126
- 7
Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K,
Nakano K.
Molecular cloning of rat leptin receptor isoform complementary DNAs: identification
of a missense mutation in Zucker fatty (fa/fa) rats.
Biochem Biophys Res Commun.
1996;
5, 225 (1)
75-83
- 8
Parish E J, Luo C, Parish S, Heideprien R W.
Selective oxidation of steroidal homoallylic alcohols using pyridium chlorochromate
(PPC).
Synthetic Communications.
1992;
22
2839-2847
- 9
Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S.
Contribution of intra-abdominal fat accumulation to the impairment of glucose and
lipid metabolism in human obesity.
Metabolism.
1987;
36 (1)
54-59
- 10
Norman M, Kaplan M D.
Deadly Quartet.
Arch Intern Med.
1989;
149
1514-1520
- 11
Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T.
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant
animals. Arznein-Forsch/Drug.
Res.
1990;
40 (1)
156-162
- 12
Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T.
Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Arznein-Forsch/Drug Res.
1990;
40 (1)
263-267
R. Konno
Technoflora Co. RIKEN
Wako-shi · Saitama · 351-0198 Japan
Phone: +81(48)467-0787 ·
Fax: +81(48)467-1347
Email: rkonno@postman.riken.go.jp
